| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Therapeutic dendritic-cell vaccine for simian AIDS.
|
Nat Med
|
2002
|
2.76
|
|
2
|
Therapeutic dendritic-cell vaccine for chronic HIV-1 infection.
|
Nat Med
|
2004
|
2.64
|
|
3
|
Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
|
J Clin Oncol
|
2005
|
2.50
|
|
4
|
The biological meaning of anti-HBC positive result in blood donors: relation to HBV-DNA and to other serological markers.
|
Rev Inst Med Trop Sao Paulo
|
2003
|
1.56
|
|
5
|
The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells.
|
Blood
|
2008
|
1.48
|
|
6
|
Predictive and discriminating three-risk-group prognostic scoring system for staging Hodgkin lymphomas.
|
Cancer
|
2007
|
1.40
|
|
7
|
Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand.
|
J Clin Oncol
|
2005
|
1.13
|
|
8
|
Molecular tracing of sexual HIV Type 1 transmission in the southwest border of China.
|
AIDS Res Hum Retroviruses
|
2008
|
1.04
|
|
9
|
Molecular epidemiological tracing of HIV-1 outbreaks in Hainan island of southern China.
|
AIDS
|
2009
|
1.03
|
|
10
|
Induction of CD8+ regulatory T cells protects macaques against SIV challenge.
|
Cell Rep
|
2012
|
0.99
|
|
11
|
Dominant effects of CCR2-CCR5 haplotypes in HIV-1 disease progression.
|
J Acquir Immune Defic Syndr
|
2004
|
0.98
|
|
12
|
Meta-analysis of randomised trials comparing gemcitabine-based doublets versus gemcitabine alone in patients with advanced and metastatic pancreatic cancer.
|
Drugs Aging
|
2007
|
0.98
|
|
13
|
What is the real impact of bone pain on survival in patients with metastatic hormone-refractory prostate cancer treated with docetaxel?
|
BJU Int
|
2009
|
0.98
|
|
14
|
Salvage therapy with bevacizumab-sunitinib combination after failure of sunitinib alone for metastatic renal cell carcinoma: a case series.
|
Eur Urol
|
2009
|
0.97
|
|
15
|
Fifteen-year secondary leukaemia risk observed in 761 patients with Hodgkin's disease prospectively treated by MOPP or ABVD chemotherapy plus high-dose irradiation.
|
Br J Haematol
|
2002
|
0.87
|
|
16
|
Expression of genes involved in chemoresistance, proliferation and apoptosis in clinical samples of renal cell carcinoma and correlation with clinical outcome.
|
Anticancer Res
|
2002
|
0.86
|
|
17
|
Variability of bio-clinical parameters in Chinese-origin Rhesus macaques infected with simian immunodeficiency virus: a nonhuman primate AIDS model.
|
PLoS One
|
2011
|
0.86
|
|
18
|
Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot.
|
Cancer
|
2008
|
0.85
|
|
19
|
Molecular epidemiology of human immunodeficiency virus type 1 in Guangdong province of southern China.
|
PLoS One
|
2012
|
0.85
|
|
20
|
Neoadjuvant dose-dense gemcitabine plus docetaxel and vinorelbine plus epirubicin for operable breast cancer: improved prognosis in triple-negative tumors.
|
Drugs R D
|
2011
|
0.82
|
|
21
|
Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.
|
Blood
|
2004
|
0.81
|
|
22
|
Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
|
Prostate
|
2007
|
0.80
|
|
23
|
Reduced versus full doses of irradiation after 3 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine in early stage Hodgkin lymphomas: results of a randomized trial.
|
Cancer
|
2010
|
0.79
|
|
24
|
Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
|
Cancer
|
2002
|
0.78
|
|
25
|
Twenty-year disease and treatment-associated mortality rates of patients with Hodgkin lymphoma of clinical stages IIIB and IV prospectively treated with 3-month anthracycline-based chemotherapy followed by extended high-dose radiation.
|
Cancer
|
2008
|
0.77
|
|
26
|
Early versus late intensification for patients with high-risk Hodgkin lymphoma-3 cycles of intensive chemotherapy plus low-dose lymph node radiation therapy versus 4 cycles of combined doxorubicin, bleomycin, vinblastine, and dacarbazine plus myeloablative chemotherapy with autologous stem cell transplantation: five-year results of a randomized trial on behalf of the GOELAMS Group.
|
Cancer
|
2008
|
0.76
|
|
27
|
T cell survival/proliferation reconstitution by trifluoperazine in human immunodeficiency virus-1 infection.
|
Virology
|
2003
|
0.76
|
|
28
|
Three cycles of adriamycin, bleomycin, vinblastine, and dacarbazine (ABVD) or epirubicin, bleomycin, vinblastine, and methotrexate (EBVM) plus extended field radiation therapy in early and intermediate Hodgkin disease: 10-year results of a randomized trial.
|
Blood
|
2003
|
0.76
|
|
29
|
Intermediate stage Hodgkin lymphoma in partial remission after three or four courses of doxorubicin, bleomycin, vinblastine dacarbazine: no benefit of one course of intensive chemotherapy before irradiation.
|
Leuk Lymphoma
|
2012
|
0.75
|